Innate Pharma to present at H.C. Wainwright 2026
Innate Pharma’s Sept. 14, 2026 4:30 PM EDT fireside chat will be live webcast with replay available via its Investors section.
Rhea-AI Filing Summary
Innate Pharma S.A. (IPHA), a clinical-stage biotechnology company focused on immunotherapies for cancer, reported that members of its executive team will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, on September 14–16, 2026. A fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast and replay accessible via the Investors section of Innate Pharma’s website. The company highlights a pipeline centered on antibody-drug conjugates, led by IPH4502 targeting Nectin-4 for solid tumors, alongside partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer.
Positive
- None.
Negative
- None.
Key Figures
Conference dates: September 14–16, 2026
Fireside chat time: 4:30 PM EDT / 10:30 PM CEST
ISIN code: FR0010331421
+2 more
5 metrics
Conference dates
September 14–16, 2026
H.C. Wainwright 28th Annual Global Investment Conference in New York, United States
Fireside chat time
4:30 PM EDT / 10:30 PM CEST
Fireside chat on September 14, 2026 during the H.C. Wainwright conference
ISIN code
FR0010331421
Identifier for Innate Pharma S.A. shares
Euronext ticker
IPH
Innate Pharma listing on Euronext Paris
Nasdaq ticker
IPHA
Innate Pharma listing on Nasdaq in the United States
Key Terms
antibody-drug conjugates (ADCs), Nectin-4, cutaneous T-cell lymphomas, non-small cell lung cancer (NSCLC), +1 more
5 terms
antibody-drug conjugates (ADCs) medical
"Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502"
Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.
Nectin-4 medical
"IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors"
A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.
cutaneous T-cell lymphomas medical
"lacutamab, developed with Sobi for cutaneous T-cell lymphomas"
A group of rare non-Hodgkin lymphomas in which cancerous T-lymphocytes primarily grow in the skin, causing patches, plaques, nodules or tumors and sometimes spreading internally. Investors care because these chronic, often slow-progressing diseases create specialized markets for diagnostics, topical and systemic therapies, and clinical trials; trial results, regulatory decisions, and new treatment approvals can materially affect companies focused on cancer drugs and dermatology.
non-small cell lung cancer (NSCLC) medical
"monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC)"
A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.
immunotherapies medical
"a clinical-stage biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
FAQ
What event is Innate Pharma (IPHA) participating in according to this 6-K?
Innate Pharma will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, taking place from September 14–16, 2026, including a fireside chat and one-on-one investor meetings.
When is Innate Pharma’s (IPHA) fireside chat scheduled at the H.C. Wainwright conference?
The fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST. A live webcast will be accessible via the Events page in the Investors section of Innate Pharma’s website, with a replay available afterward.
How can investors access the Innate Pharma (IPHA) fireside chat webcast?
Investors can access the live webcast of the fireside chat through a link on the Events page of the Investors section of Innate Pharma’s website. A replay will be made available following the event.
What is the core focus of Innate Pharma’s (IPHA) proprietary pipeline?
Innate Pharma’s proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a Nectin-4 ADC in clinical development for solid tumors, alongside a preclinical portfolio of next-generation ADC candidates.
Which late-stage partnered assets does Innate Pharma (IPHA) highlight in this report?
Innate Pharma highlights two late-stage partnered assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).
AI-generated analysis. How Rhea-AI works. Not financial advice.
